WASHINGTON – FDA drug reviewers in documents released Friday unsurprisingly focused on safety issues with Orexigen Therapeutics Inc.'s experimental weight-loss pill Contrave (naltrexone/bupropion), with the risks of adverse cardiovascular, psychiatric and cognitive events, along with seizures and increased serum creatinine among the agency's top concerns. Read More
